Arendt advises Alvotech on all Luxembourg law aspects on a private placement of SEK 750 million

Experts involved in the Deal

Arendt & Medernach has successfully advised Alvotech, a global biotech leader in biosimilar medicine development and manufacturing, on the Luxembourg legal aspects of its recent private placement.

The transaction raised gross proceeds of SEK 750 million through the placement of Swedish Depositary Receipts (SDRs) and ordinary shares to Swedish and international institutional investors. The offering was conducted via an accelerated bookbuilding process, with the securities being made available through Alvotech’s existing treasury shares.

Alvotech maintains a distinctive multi-exchange presence with its securities listed on the Nasdaq Iceland Main Market, Nasdaq Global Market in the United States, and Nasdaq Stockholm (in the form of SDRs).

The Arendt team provided comprehensive guidance on Luxembourg capital markets, corporate and tax law matters throughout the transaction.